Ovarian Cancer Trial, Recruiting NCT07075939 Sponsor: Azienda USL Reggio Emilia - IRCCS Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT07075939
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are female and aged between 18 and 99 years
  • People who have been diagnosed with epithelial ovarian cancer confirmed through tissue or cell testing
  • People whose case was reviewed by the Multidisciplinary Tumor Board at the AUSL-IRCCS hospital in Reggio Emilia, Italy
  • People who received treatment between January 1, 2018, and December 31, 2023
  • People whose medical records and health outcome information are available
  • People who have signed an informed consent form where possible, in line with privacy laws in Italy and the EU

Who may not be able to join:

  • People who do not have a confirmed diagnosis of epithelial ovarian cancer through tissue or cell testing
  • People whose medical records are incomplete or have key clinical information missing
  • People who are unable to give informed consent and cannot be contacted by the trial team
  • People who are considered unable to understand and agree to consent due to reasons such as severe cognitive impairment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vincenzo Dario Mandato, MD, Azienda USL - IRCCS di Reggio Emilia

Phone: +39 0522 295467

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda USL Reggio Emilia - IRCCS
Registry
ClinicalTrials.gov
Start date
27 June 2025
Est. completion
1 June 2030

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Progression-Free Survival (PFS); Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov